# clm_36AD989DA75C

subject: Eli Lilly and Company (/record/eli-lilly.md)  
predicate: quarterly_research_and_development  
value: 1,610,100,000 United States dollar  
valid_from: 2022-03-31  
valid_to: 2022-06-30  
published: 2022-04-29  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_7E87516D4A1A  
last_updated: 2026-11-08  
cite: AsOf. "Eli Lilly and Company quarterly research and development: 1,610,100,000 United States dollar", as of 2022-03-31 (until 2022-06-30). Claim clm_36AD989DA75C, https://asof.is/claim/clm_36AD989DA75C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000133/0000059478-22-000133-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2022, filed 2022-04-29  

## Sources

- https://www.sec.gov/Archives/edgar/data/59478/000005947822000133/0000059478-22-000133-index.htm (primary, SEC EDGAR 10-Q Q1 FY2022, published 2022-04-29)

## Supersedes

- [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_research_and_development | 1,708,900,000 United States dollar | valid 2021-09-30 to 2022-03-31 | conf 0.95 | superseded | superseded_by [clm_36AD989DA75C](/claim/clm_36AD989DA75C.md) | [clm_0D1C949297F8](/claim/clm_0D1C949297F8.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.